Abstract:The epidemiological burden of liver steatosis associated with metabolic diseases is continuously growing worldwide and in all age classes. This condition generates possible progression of liver damage (i.e., inflammation, fibrosis, cirrhosis, hepatocellular carcinoma) but also independently increases the risk of cardio-metabolic diseases and cancer. In recent years, the terminological evolution from "nonalcoholic fatty liver disease" (NAFLD) to "metabolic dysfunction-associated fatty liver disease" (MAFLD) and, finally, "metabolic dysfunction-associated steatotic liver disease" (MASLD) has been paralleled by increased knowledge of mechanisms linking local (i.e., hepatic) and systemic pathogenic pathways. As a consequence, the need for an appropriate classification of individual phenotypes has been oriented to the investigation of innovative therapeutic tools. Besides the well-known role for lifestyle change, a number of pharmacological approaches have been explored, ranging from antidiabetic drugs to agonists acting on the gut–liver axis and at a systemic level (mainly farnesoid X receptor (FXR) agonists, PPAR agonists, thyroid hormone receptor agonists), anti-fibrotic and anti-inflammatory agents. The intrinsically complex pathophysiological history of MASLD makes the selection of a single effective treatment a major challenge, so far. In this evolving scenario, the cooperation between different stakeholders (including subjects at risk, health professionals, and pharmaceutical industries) could significantly improve the management of disease and the implementation of primary and secondary prevention measures. The high healthcare burden associated with MASLD makes the search for new, effective, and safe drugs a major pressing need, together with an accurate characterization of individual phenotypes. Recent and promising advances indicate that we may soon enter the era of precise and personalized therapy for MASLD/MASH.

The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions

Organ damage proteomic signature identifies patients with MASLD at-risk of systemic complications.

Applying Proteomics in Metabolic Dysfunction-Associated Steatotic Liver Disease: from Mechanism to Biomarkers

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression

Deep Proteome Profiling of Metabolic Dysfunction-Associated Steatotic Liver Disease

A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis

Updated mechanisms of MASLD pathogenesis

From Pathogenesis to Current Therapeutic Options

A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD

Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we?

Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches

Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment

Multiscale integrative analyses unveil immune-related diagnostic signature for the progression of MASLD

MASLD: What We Have Learned and Where We Need to Go-A Call to Action

Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis

Envisioning how to advance the MASH field

Unbiased Phosphoproteome Mining Reveals New Functional Sites of Metabolite-Derived PTMs Involved in MASLD Development

Therapeutic management of metabolic dysfunction associated steatotic liver disease

Drug repurposing in MASLD and MASH-cirrhosis: Targets and treatment approaches based on pathways analysis